Researchers Identify Immune 'Brake' That Limits Cancer Immunotherapy

Researchers at the University of Montreal have identified a previously unknown mechanism that allows cancer cells to evade the immune system. The study, led by Dr. André Veillette and published in the journal Nature, highlights a molecule called SLAMF6 that acts as an internal 'brake' on T cells. Unlike other immune checkpoints that require external signals from tumor cells to function, SLAMF6 can self-activate on the surface of T cells, leading to immune exhaustion and a diminished capacity to fight tumors.

This discovery is significant because it addresses a major limitation in current oncology. While existing immunotherapies, such as PD1 and PDL1 inhibitors, have revolutionized cancer care, many patients eventually develop resistance or fail to respond to these treatments entirely. By uncovering how SLAMF6 independently suppresses immune function, the research team has identified a new target for therapeutic intervention that operates outside the traditional pathways currently addressed by clinical medicine.

To combat this, the team developed specialized monoclonal antibodies designed to block SLAMF6 from triggering its suppressive signals. In preclinical models, these antibodies successfully prevented T cell exhaustion, promoted the development of durable immune cells, and demonstrated robust anti-tumor activity. These findings suggest that blocking SLAMF6 could provide a powerful new strategy to reinvigorate the immune system, either as a standalone treatment or in combination with existing therapies.

Looking ahead, the researchers are preparing for early-stage clinical trials to assess the safety and efficacy of these antibodies in human patients. If successful, this approach could offer a vital new option for individuals with solid tumors and blood cancers who have exhausted other treatment avenues, marking a promising advancement in the field of precision immunotherapy.